| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/20/2023 | 5.47% | Truist Securities | → $215 | Reiterates | Buy → Buy |
| 08/07/2023 | 12.34% | Morgan Stanley | $188 → $229 | Upgrades | Equal-Weight → Overweight |
| 08/04/2023 | 11.85% | Baird | $200 → $228 | Maintains | Outperform |
| 07/21/2023 | 3.51% | Truist Securities | $190 → $211 | Maintains | Buy |
| 07/19/2023 | 0.07% | Stifel | $200 → $204 | Maintains | Buy |
| 05/19/2023 | — | William Blair | Reinstates | → Outperform | |
| 04/17/2023 | -1.89% | Stifel | $196 → $200 | Maintains | Buy |
| 02/23/2023 | -6.79% | Truist Securities | $183 → $190 | Maintains | Buy |
| 12/12/2022 | -7.78% | Morgan Stanley | $187 → $188 | Downgrades | Overweight → Equal-Weight |
| 11/07/2022 | -8.27% | Morgan Stanley | $180 → $187 | Maintains | Overweight |
| 10/11/2022 | -19.06% | Stifel | $162 → $165 | Maintains | Buy |
| 10/11/2022 | -16.61% | Wolfe Research | → $170 | Initiates Coverage On | → Outperform |
| 07/19/2022 | -18.57% | Truist Securities | $167 → $166 | Maintains | Buy |
| 07/18/2022 | -23.96% | Stifel | $168 → $155 | Maintains | Buy |
| 03/01/2022 | -7.28% | Morgan Stanley | $180 → $189 | Maintains | Overweight |
| 01/21/2022 | -16.61% | Berenberg | → $170 | Initiates Coverage On | → Buy |
| 12/03/2021 | -11.7% | Morgan Stanley | → $180 | Initiates Coverage On | → Overweight |
| 09/29/2021 | -22.98% | Baird | $134 → $157 | Upgrades | Neutral → Outperform |
| 01/07/2021 | -41.62% | Baird | → $119 | Downgrades | Outperform → Neutral |
| 05/08/2020 | -31.81% | Stifel | $145 → $139 | Maintains | Buy |
| 04/17/2020 | -36.23% | UBS | $160 → $130 | Maintains | Buy |
| 04/16/2020 | -43.59% | SunTrust Robinson Humphrey | $150 → $115 | Maintains | Buy |
| 02/28/2020 | -26.42% | SunTrust Robinson Humphrey | $157 → $150 | Maintains | Buy |
| 02/28/2020 | -21.51% | UBS | $165 → $160 | Maintains | Buy |
| 01/15/2020 | -19.06% | UBS | $145 → $165 | Upgrades | Neutral → Buy |
| 11/01/2019 | -28.87% | UBS | $134 → $145 | Maintains | Neutral |
| 07/15/2019 | -27.89% | Stifel | $138 → $147 | Maintains | Buy |
| 03/01/2019 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 02/28/2019 | -31.32% | Baird | $123 → $140 | Maintains | Outperform |
| 12/19/2018 | -40.15% | Stifel | $120 → $122 | Upgrades | Hold → Buy |
What is the target price for Curtiss-Wright (CW)?
The latest price target for Curtiss-Wright (NYSE: CW) was reported by Truist Securities on October 20, 2023. The analyst firm set a price target for $215.00 expecting CW to rise to within 12 months (a possible 5.47% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Curtiss-Wright (CW)?
The latest analyst rating for Curtiss-Wright (NYSE: CW) was provided by Truist Securities, and Curtiss-Wright reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Curtiss-Wright (CW)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Curtiss-Wright, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Curtiss-Wright was filed on October 20, 2023 so you should expect the next rating to be made available sometime around October 20, 2024.
Is the Analyst Rating Curtiss-Wright (CW) correct?
While ratings are subjective and will change, the latest Curtiss-Wright (CW) rating was a reiterated with a price target of $0.00 to $215.00. The current price Curtiss-Wright (CW) is trading at is $203.85, which is within the analyst's predicted range.